This article was downloaded by:[EBSCOHost EJS Content Distribution]

This article was downloaded by:[EBSCOHost EJS Content Distribution]
On: 18 February 2008
Access Details: [subscription number 768320842]
Publisher: Psychology Press
Informa Ltd Registered in England and Wales Registered Number: 1072954
Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK
Publication details, including instructions for authors and subscription information:
Pharmacological approaches to the treatment and
prevention of aphasia
Rebecca J. Shisler; Gordon C. Baylis; Elaine M. Frank
Online Publication Date: 01 December 2000
To cite this Article: Shisler, Rebecca J., Baylis, Gordon C. and Frank, Elaine M.
(2000) 'Pharmacological approaches to the treatment and prevention of aphasia',
Aphasiology, 14:12, 1163 - 1186
To link to this article: DOI: 10.1080/02687030050205705
Full terms and conditions of use:
This article maybe used for research, teaching and private study purposes. Any substantial or systematic reproduction,
re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly
The publisher does not give any warranty express or implied or make any representation that the contents will be
complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be
independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings,
demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or
arising out of the use of this material.
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
APHASIOLOGY, 2000, 14 (12), 1163–1186
Pharmacological approaches to the treatment and
prevention of aphasia
Rebecca J. Shisler
University of Georgia, USA
Gordon C. Baylis and Elaine M. Frank
University of South Carolina, USA
Strokes cause a variety of cognitive impairments that may include aphasia. Speech-language
pathologists and aphasiologists encounter an increasing number of patients treated with
pharmacological agents. This review describes research regarding four main approaches to
neuropharmacological intervention: pharmacotherapy or drugs used to facilitate language
improvements following stroke, neuroreplacement to restore compromised levels of
neurotransmitters, neuroprotective agents that minimise the extent of cell loss in the brain,
and thrombolytic agents to restore blood flow to regions of the brain that have become
ischaemic following stroke. Studies in each major approach are reviewed.
Recent trends in pharmacological treatment of aphasia and stroke have led to new therapy
developments in rehabilitation. These trends have built on past successes and failures to
produce realistic possibilities for treatment and prevention of aphasia. This paper is a
review for speech-language pathologists of pharmacological approaches to the treatment
of stroke and secondary aphasia. As more patients are treated with pharmacological
interventions, awareness of these interventions is becoming ever more important. In order
to understand why certain drugs have succeeded while others have failed, it is first
important to briefly review what occurs during a stroke and the subsequent deficits.
The process of stroke
There are two types of strokes: haemorrhagic and ischaemic. Ischaemic strokes represent the
majority of all strokes, accounting for approximately 80% of clinical cases, and will be the
primary focus of this review. Nonetheless, it should be noted that many of the principles for
psychopharmacological intervention may also transfer to haemorrhagic strokes. When an
ischaemic stroke occurs, three zones of damage form concentric circles, similar to a bullseye
target. The primary area of damage is the central ischaemic zone (the ‘‘centre’’ of the
Address correspondenc e to: Rebecca J. Shisler, Department of Communication Sciences and Disorders, 528
Aderhold Hall, The University of Georgia, Athens, GA 30602, USA. Email: [email protected]
The authors would like to thank Drs R.R. Robey and Richard C. Gilman for their time and helpful comments
on this article.
Ó 2000 Psychology Press Ltd
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
bullseye), where loss of oxygen contributes to an inflammatory reaction (Matsuo, Yamasaki,
& Kogure, 1996), leading to tissue destruction in this zone. Surroundin g this central zone is
the ischaemic penumbra in which blood flow is reduced but cell function is only temporarily
depressed (Benson & Ardila, 1996). Damage to this penumbra is potentially reversible, if
intervention is timely, and so this is the main target for pharmacological and other medical
intervention. The final, outermost ring, termed the collateral zone, contains little or no tissue
damage, thus requiring minimal treatment (Matsuo et al., 1996).
After an ischaemic event, a chain of events referred to as ‘‘the calcium cascade’’
occurs (Brailowsky, 1988). This cascade begins with failure of the sodium-potassium
pump and other energy-dependent mechanisms for regulating intracellular ion
concentrations. Failure of the sodium-potassium pump allows sodium to flow into the
cell, causing cytotoxic oedema and changes in the cell’s ionic balance. The resulting
failure of mechanisms also leads to a significant increase in the amount of intracellular
calcium, initiating the main events of the calcium cascade proper (Scheinberg, 1991;
Siesjo, 1992; Turkstra, 1997). Increased intracellular calcium levels lead to release of a
number of excitatory neurotransmitters (such as glutamate) that can bring about
excitotoxic neuronal death. The cumulative effects of these transmitters leads to an
increased influx of calcium into neighbouring cells, thus initiating a spiralling
intensification of the effects of ischaemia (Rothman, 1983; Scheinberg, 1991).
An increase in intracellular calcium also activates many autolytic enzymes that further
break down the cell’s protein, DNA, and lipids that form an essential part of the cell’s
membrane (Turkstra, 1997). Moreover, the breakdown of lipids leads to the production of
arachidonic acid and subsequent formation of free radicals (Reilly & Bulkley, 1990). Free
radicals are highly unstable molecules that cause rapid oxidation of biological molecules
(Reilly & Bulkley, 1990). Although free radicals are formed during normal cell
functioning, antioxidants and free radical scavengers neutralise them as part of the
normal neuroprotective defence mechanisms (Turkstra, 1997). However, when there is
low energy availability during an ischaemic event, free radicals are not efficiently
scavenged. Therefore, the free radicals may react with molecules in cells, causing further
deterioration (Fishman, 1986; Reilly & Bulkely, 1990).
This cascade of dysfunction highlights three crucial areas for treatment and
neuroprotection: the re-establishment of regulation of intracellular calcium, the
regulation of excitatory neurotransmitters, and the containment of free radicals. Research
in animal models of stroke suggests that these events take place over hours or days
(Dyker & Lees, 1998). Thus, the window for intervention may in fact extend beyond the
first few hours after the ischaemic event. With increasing knowledge of the mechanisms
and time course of damage, a number of new drugs have been developed to address the
cellular injury caused by stroke.
Deficits associated with stroke
Secondary impairments after a stroke include hemiparesis and deficits in vision, audition,
cognition, and language including aphasia. Aphasia impairs an individual’s expressive
and/or receptive language, and many people never recover the ability to communicate or
process information (Hegde, 1994). More specifically, Darley (1982, p. 42) defined
aphasia as:
Impairment, as a result of brain damage, of the capacity for interpretation and formulation of
language symbols; multimodality loss or reduction in efficiency of the ability to decode and
encode conventional meaningful linguistic elements (morphemes and larger syntactic units).
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
In the past, research has focused on rehabilitating individuals with aphasia primarily by
using language therapy. Recent research has suggested that a more aggressive treatment
regimen may be appropriate. One potentially productive research area is to attempt to
protect brain tissue from permanent damage during the course of a stroke (i.e.,
neuroprotection). Because, as noted above, a large part of the damage site of a stroke (the
penumbra) does not initially suffer irreversible damage, timely and appropriate
pharmacotherapeutic intervention may prevent much of the brain damage, thus mitigating
many of the deficits associated with stroke. With the advent of more and more
pharmacological agents following stroke, it is increasingly important for speech-language
pathologists to be aware of past and current approaches to drug treatment in stroke and
secondary aphasia.
Main approaches to treatment
Four essential models of treatment that will be discussed in this review are:
pharmacotherapy, neuroreplacement, neuroprotective agents, and thrombolytics (see
Table 1). Pharmacotherapy refers to the use of drugs to facilitate language improvements
following stroke. This area has a long history of research and has been essential in
stimulating additional research into pharmacological approaches to the treatment of
aphasia. A similar approach to optimising maximum rehabilitation is neuroreplacement,
which focuses specifically on the neurotransmitter systems of the brain. Although this
approach can be considered a subset of pharmacotherapeutic approaches, it operates on a
different premise then conventional pharmacotherapy. Specifically neuroreplacement
seeks to replace the neurotransmitters that were lost following stroke. This replacement in
turn is believed to improve language function in individuals with aphasia. Thus a
neuroreplacement section will be discussed separately.
In contrast to these two approaches, two other approaches are directed at minimising
the initial damage that occurs following a stroke. Neuroprotective agents attempt to
Drug categories and research type and status
Type of research
Status of use in humans
Tissue Plasminogen Activator
Neuroprotective agent
Neuroprotective agent
Neuroprotective agent
Neuroprotective agent
Neuroprotective agent
Neuroprotective agent
Neuroprotective agent
Neuroprotective agent
Neuroprotective agent
Neuroprotective agent
Neuroprotective agent
* Found ineffective in treating aphasia
** Discontinued in Europe
Discontinued (12/97)
Discontinued (1995)
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
interrupt the chemical processes that lead to cell death in the ischaemic penumbra, thus
minimising the extent of damage. This approach thus decreases the extent of deficits,
reducing the need for rehabilitation of lost language functioning. Finally, thrombolytic
agents are used to re-establish blood supply to the affected area of the brain as soon as
possible, reducing the duration of the ischaemic episode. Although fundamentally
different from the chemical neuroprotective approach, the effect is the same—to
minimise the extent of destroyed tissue, reducing the deficits and the need for
The notion of pharmacotherapy to assist in the recovery of function in aphasic individuals
is not new, although recent improvements in understanding the biochemical nature of
stroke damage are leading to increased scholarship in this area. Research in the area of
pharmacology primarily focused on two areas: frustration reduction and increased blood
Frustration reduction
Early pharmacotherapy attempts in aphasia were based on the observed frustration among
patients suffering from stroke. For example, Linn (1947) hypothesised that by lessening
the frustration and inhibition of communication found in aphasia, language functioning
could increase. Using the sedative sodium amytal, Linn reported that one woman with
mixed aphasia demonstrated significant improvement in object naming and function
naming tasks and on the Goldstein-Scheerer block test (Goldstein & Scheerer, 1945). In
this study, a second woman was also administered the same amount of solution, resulting
in similar improvements. However, this woman relapsed immediately after the effects of
the drug dissipated. Linn (1947) surmised that sodium amytal may not necessarily change
the underlying neuronal mechanisms that cause aphasia, but may temporarily increase
verbal expression by lowering the frustration level of the individuals. Billow (1949) also
reported temporary relief of aphasia in two patients when using sodium amytal.
Nevertheless, subsequent studies using sodium amytal have reported conflicting findings.
For example, in an investigation of 27 patients, Bergman and Green (1951) found a
significant decrease in the language skills of patients with aphasia after administering
sodium amytal.
Despite these equivocal findings with sodium amytal, numerous investigators
continued to pursue the hypothesis that reducing a patient’s frustration after aphasia
would increase their language abilities. West and Stockel (1965) investigated the effects
of meprobamate (a tranquilliser) on the language performance of 29 subjects. The results
indicated that the use of meprobamate, in combination with language therapy, did not
significantly increase language performance among those in the experimental group in
comparison to those who received language therapy and placebo. Along a similar
hypothesis, Darley, Keith, and Sasanuma (1977) investigated the effects of Ritalin (a
psychostimulant) and Librium (a tranquilliser) on reducing anxiety and increasing
alertness with the goal of improving linguistic cognitive performance. In this study, 14
patients diagnosed with aphasia were administered Ritalin, Librium, or a placebo across a
three-day period. The specific drug or placebo was given 45 minutes prior to
administration of the Porch Index of Communicative Ability (PICA; Porch, 1983) and
a word fluency test. This design allowed for comparisons to be made within each subject.
Subsequent results revealed no difference between the drugs or the placebo on patients’
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
performance on either assessment. In general, little support has been found regarding the
hypothesis that reducing an aphasic patient’s frustration level would enhance their ability
to communicate.
Increasing oxygenation
In contrast, a competing hypothesis within the area of pharmacotherapy speculates that
increasing blood flow to the cerebral area may improve oxygenation, hence restoring
functioning of partially damaged neuronal tissue. This oxygenation would in turn
increase the language performance among individuals with aphasia. In this vein,
Hemphill (1951) reported findings of short-term improvements (three hours) with an
increase in speech fluency and sentence copying after administration of Priscol. Given the
short-term effects of Priscol, Hemphill hypothesised that the cerebral structures that were
not functioning in aphasia were functionally depressed rather than destroyed. This
hypothesis can be viewed as an early characterisation of the ischaemic penumbra, with
only temporarily depressed cell function that may be salvaged.
In addition, Smith and Turton (1951) reported a dramatic improvement in verbal
fluency and verbosity in a man with mixed aphasia after receiving 40 mg of Priscol (an
antiadrenergic, peripheral vasodilator drug). In spontaneous speech, Smith and Turton
reported that this improvement lasted for three hours, and suggested that the patient
demonstrated ‘‘a good performance on learning tests and no evidence of memory
failure’’ (Smith & Turton, 1951, p.891), although the outcome measures and
experimental procedure of this study were not reported. Smith and Turton postulated
that the effects were due to Priscol’s action as a dilator of brain arterioles, leading to an
improved oxygen supply to the brain. However, some limitations in the design and the
nature of the study should be noted. For example, assessment of this study is difficult due
to the informal nature of testing and the lack of experimental details. In fact, in
subsequent trials, the patient slowly returned to baseline after showing initial
improvement, in spite of dosage increases (Smith & Turton, 1951).
Hyperbaric oxygen has also been utilised in attempts to improve language functioning
in individuals with aphasia (Sarno, 1969). For example, Sarno, Sarno, and Diller (1972b)
exposed 16 participants to hyperbaric oxygen for 112 hours. Baseline measures were taken
24 hours before the first exposure and participants were then retested immediately
following use of the hyperbaric chamber. Sarno et al. (1972b) found no significant
improvements on the Token Test (De Renzi & Vignolo, 1962) and the Functional
Communication Profile (FCP; Taylor, 1965). In a follow-up study (Sarno, Rusk, Diller, &
Sarno, 1972a), 32 stroke patients with aphasia were administered portions of the
Wechsler Adult Intelligence Scale (WAIS), the Token Test, and the FCP for
communication assessment before, during, and after exposure to hyperbaric oxygen.
Similar to the earlier Sarno et al. (1972b) study, hyperbaric oxygen did not improve the
cognitive or communication functioning of these aphasic individuals (Sarno et al.
1972a, b).
In sum, attempts at pharmacological interventions have yielded equivocal success. The
frustration reduction hypothesis has generally produced ambiguous and conflicting
results, with apparent improvements largely due to biases inherent in the methodology
rather than the treatment per se. Subsequent investigations of this hypothesis using more
stringent methodology have generally yielded non-significant findings. In addition, the
increasing oxygenation hypothesis showed limited and short-term effects on a patient’s
language, if improvements were seen at all. Therefore, it appears both the frustration
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
reduction and increasing oxygenation hypotheses may only help to improve language on
a limited and temporary basis, if at all.
A more recent approach to pharmacological rehabilitation following stroke concerns the
replacement of lost neurotransmitters, or neuroreplacement. According to this view, the
replacement or augmentation of neurotransmitter systems in the brain is thought to play a
role in the recovery from stroke and its subsequent deficits including aphasia. One of the
early precursors to this approach might have been through the use of certain foods (see
Bachman & Albert, 1990). For example, previous stroke research hypothesised that
individuals given roots and cashew nuts would demonstrate increased language
performance. Such foods are rich in amino acids that serve as precursors to
neurotransmitters, and it is possible they replaced lost neurotransmitters and therefore
aided in recovery (Mettler, 1947; Mlcoch & Gupta, 1995). More contemporary theories
focus on both the catecholaminergic and GABA-minergic neurotransmitter systems as
sources of neuroreplacement, as both have been suggested to play a role in the recovery
of language following stroke. Many researchers have argued that a combination approach
of speech-language therapy with these pharmacological interventions increasing
neurotransmitters will lead to an increase in functional language recovery (Enderby et
al., 1994; Walker-Batson et al., 1992). The following sections will discuss drug
administration alone as well as combining therapy with drug interventions in regards to
the two major systems targeted in neuroreplacement. The two major systems include: the
catecholamine system and the GABA-minergic system.
Catecholamine systems
Theories of the effect of catecholaminergic systems on language recovery were initially
based on improvements after amphetamine administration (see Mlcoch & Gupta, 1995;
Small, 1994; Walker-Batson et al., 1992). Amphetamine is known to have effects on two
distinct catecholaminergic systems: the norepinephrine and dopamine systems. Some
researchers have argued that changes in norepinephrine functioning after stroke show a
relationship with rate of recovery after brain injury (e.g., Feeney, Gonzales, & Law,
1982). Thus, in order to determine the effects of amphetamine in the recovery of speech
and language functioning, Walker-Batson et al. (1990) studied a man diagnosed with
moderate-to-severe Broca’s aphasia. Amphetamine was administered approximately 45
minutes prior to a 75-minute speech and language therapy session every 4 days across a
6-week period. Instead of using an explicit control in this study, the improvement in this
patient was compared to known normative recovery, using Porch’s prediction method
(Porch, 1981). The prediction method calculated that the patient would be expected to
improve by 3.8 points, and the patient actually achieved a 16-point ‘‘Target Difference
Score’’ at 6 months post-onset. Similar improvements were also noted at 12 months postonset, again exceeding the improvement that would be predicted without intervention. It
must be noted that due to the single-subject study design (and therefore only descriptive
results), it is difficult to isolate the true therapeutic effect of amphetamine, as opposed to
the effects of the speech-language therapy or spontaneous recovery. Because of this
limitation, Walker-Batson et al. (1992) replicated the study with six participants
diagnosed with aphasia according to the Porch Index of Communicative Ability (PICA).
The authors again compared the improvements seen with intervention to the baseline
improvements predicted by the Porch (1981) method. Results indicated that at just 3
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
months post-onset, five of the six patients achieved 100% of the predicted 6 month PICA
scores—a dramatic improvement over predicted recovery. Taken together, these findings
suggest the possibility that the use of amphetamines in conjunction with speech and
language therapy may aid in the recovery of aphasia. Nevertheless, given the lack of
control groups, these results should be interpreted with caution until more stringent
studies are designed.
Further support for the efficacy1 of amphetamines in treating deficits following stroke
comes from studies where the use of the drug was combined with intense physical
therapy for disorders other than aphasia. Crisostomo, Duncan, and Dawson (1988) gave
eight patients with right hemisphere stroke a combination of amphetamines and physical
therapy. After comparing recovery with individuals who received physical therapy alone,
significant improvements were found in the group that received amphetamines in
addition to physical therapy. Similarly in a randomised double-blind placebo-controlled
study, Walker-Batson et al. (1995) reported full recovery of motor control in five patients
receiving this combination therapy, even when tested 12 months after completion of the
study. In view of the effect on motor function, Hassid (1995) suggested that the apparent
success of amphetamine in treating aphasia is mediated by its effects on motor function—
an essential component in the formation of speech.
Other researchers have argued that dysfunction of the dopaminergic system may lead
to impaired fluency in patients diagnosed with nonfluent aphasia. This suggests that the
effects of amphetamine may be mediated via its dopaminergic system (e.g., Bachman &
Albert, 1990; Freedman, Alexander, & Naeser, 1984). Indeed, Freedman et al. (1984)
found that lesions in the dopamine tracts of the left dorsal and medial frontal areas
(especially the left supplementary motor area) corresponded to significant decreases in
speech initiation. Based on this finding, subsequent research has sought to increase
dopamine activity using bromocriptine, a dopamine agonist that, unlike amphetamine,
has no effect on the norepinephrine system.
In one early study using bromocriptine, Albert, Bachman, Morgan, and HelmEstabrooks, (1988) attempted to improve the language performance of an individual
diagnosed with transcortical motor aphasia. Using the Boston Diagnostic Aphasia Exam
(BDAE; Goodglass & Kaplan, 1983) as the outcome measure, the researchers noted
improved language performance after 10 days of treatment. The investigators also
reported continued improvement in language performance after 1 month of treatment,
although improvement became markedly slower as the duration of the treatment
progressed. When bromocriptine use was discontinued for one month, the patient
exhibited a complete return to baseline performance. Albert et al. (1988, p. 878) noted
that ‘‘formal language testing . . . failed to capture his dramatic gains in conversational
fluency’’, indicating that bromocriptine might have alleviated some of the language
deficits of the individual. However, this study was a single-subject design and did not use
a placebo control, thereby limiting the strength of the conclusions that can be drawn.
Noting this limitation, MacLellan, Nicholas, Morley, and Brookshire, (1991)
investigated the effects of bromocriptine in doses ranging between 2.5 and 20 mg, on
a man diagnosed with transcortical motor aphasia. This study employed single-blind
procedures, using either bromocriptine or a placebo over a 4-week period. Results
indicated no significant improvement in language performance of the participant.
For the purpose of this article, we have adopted the definition of efficacy such that it refers to the extent to
which a specific intervention, procedure, regimen, or service produces a beneficial result under ideal
circumstances (Last, 1995).
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
Unfortunately, MacLellan et al. (1991) used only parts of the BDAE to determine
improvement, once again limiting the ability to compare this investigation with others.
Nonetheless, it is tempting to conclude that the ‘‘unequivocal improvement’’ that Albert
et al. (1988, p. 878) noted may be due to the lack of a placebo condition. Without a
measurement of spontaneous recovery it is difficult to determine the effect of the
intervention itself. In addition, both studies were single-subject designs, thus limiting
their generalisability.
In a more recent study, Gupta and Mlcoch (1992) studied two patients with nonfluent
aphasia more than 18 months post-stroke. The patients were given both 10 mg and 30 mg
of bromocriptine, beginning with 10 mg per day during the first week and increasing to
daily doses of 30 mg over 8 weeks. The researchers obtained a 10- to 15-minute speech
sample and administered the BDAE and The Boston Naming Test (BNT; Kaplan,
Goodglass, & Weintraub, 1993). Both patients demonstrated an increase in the number
and type of words used as measured by these assessments. However, because of
methodological limitations of the study (e.g., no placebo control group), the results must
be interpreted with caution due to the fact that spontaneous recovery may have
contributed to the increasing speech fluency.
Sabe, Leiguarda, and Starkstein (1992) administered various doses of bromocriptine
(15, 30, 45, and 60 mg) to seven participants diagnosed with various severities and types
of aphasia. The Western Aphasia Battery (WAB; Kertesz, 1979, 1982) was used for
assessment of language performance every two weeks. Sabe et al. (1992) hypothesised
that ‘‘bromocriptine may significantly improve language disturbances in patients with
moderate, but not severe, nonfluent aphasia’’ (p.42). In this particular study,
improvement was only seen when moderately large doses of the drug were administered.
These doses were higher than those used in the study of MacLellan et al. (1991), in which
no beneficial effect of bromocriptine was observed. Thus, improvement in language
performance may be a function of dosage level. Nevertheless, while Sabe et al.’s (1992)
finding showed promise for individuals with moderate forms of nonfluent aphasia, some
potential limitations were noted. First, a caveat has to be placed on the use of these doses
of bromocriptine, as all patients administered the highest doses experienced painful side
effects, including dystonias (bizarre movements of the arms, legs, neck, and face)
(Ciccone, 1996). The second caveat comes from the fact that the study did not employ a
double-blind, placebo-controlled design. Indeed, in a follow-up study that did use
appropriate controls, Sabe et al. (1995), failed to replicate this improvement in seven
patients diagnosed with various levels of severity and types of aphasia.
In summary, bromocriptine studies have produced conflicting results. Typically, wellcontrolled studies have shown that the use of bromocriptine does not produce any
improvement in the degree of recovery compared to that seen in the controls. The
suggestion that bromocriptine may have beneficial effects has come from studies that
include experimental confounds, such as placebo effects, experimenter bias, the influence
of behavioural therapy, and spontaneous recovery.
GABA-minergic system
A second target of neuroprotective therapy is the GABA-minergic system. Gammaamniobutyric acid (GABA) plays a role in the events associated with a stroke and is
thought to interact closely with glutamate (Schallert & Hernandez, 1998). In addition,
GABA also interacts with other neurons (e.g., noradrenergic and cholinergic), which are
associated with recovery of function (Francis & Pulsinelli, 1982; McIntosh, 1994; Metz,
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
1971; Schallert & Hernandez, 1998). Therefore, the GABA-minergic system is important
in relation to recovery after ischaemia.
One drug that is thought to act as a GABA agonist is Piracetam, although its exact
mode of action is unknown (Bachman & Albert, 1990). Piracetam is in a class of drugs
called nootropics, or drugs that enhance cognitive function, and has been used in a
number of studies investigating cognitive recovery following stroke (Cohen & Muller,
1993; Hickenbottom & Grotta, 1998; Stoll, Schubert, & Muller, 1991). How this, and
other drugs lead to the functional effect of improved cognition is much debated, but
nootropic agents may act by increasing the density and restoring the function of
muscarinic (Stoll et al., 1991) and NMDA receptors (Cohen & Muller, 1993). In an early
study, Stolyarova et al., (1978) administered Piracetam to 35 patients with aphasia and
reported a significant improvement in speech and language recovery for 20 of them
(57%). Similar findings have been reported in more recent studies (e.g., Von Herrschaft,
1987; Willmes, Huber, Poeck, & Poersch, 1988). In one such study, patients with mild to
moderate language losses were found to improve if treatment began shortly after the
onset of the stroke (Willmes et al., 1988). Von Herrschaft (1987) also found
improvements in individuals with aphasia when using nootropic agents.
In a double-blind parallel-group study, Huber et al. (1997) studied the effects of
Piracetam on 50 individuals with aphasia. Over a 6-week period the investigators gave a
combination of the drug treatment and intensive speech-language therapy. The
experimental group received 4.8 g of Piracetam every day and the control group
received a placebo on the same schedule. At the end of 6 weeks, the group receiving
Piracetam scored significantly higher than the placebo group on the Written Language
and Token Test subtests of the Aachen Aphasia Test (AAT; Willmes, Poeck, Weniger, &
Huber, 1980). Unfortunately, no follow-up was carried out to assess the long-term
significance of this improvement. Enderby et al. (1994) conducted a double-blind
parallel-group study, in which participants were randomly assigned to receive 4.8 g of
Piracetam or placebo each day for 12 weeks. All participants received speech and
language therapy during the study. Drug efficacy was assessed with the AAT, a rating of
activities of daily living (ADL) using the Barthel Index (Mahoney & Barthel, 1965), and
the Kuriansky Performance Test (Kuriansky & Gurland, 1976), and tests of perception
(Rivermead Perception Assessment Battery; Whiting, Lincoln, Bhavani, & Cockburn,
1985). Tests were administered at the beginning of the study, at 5 weeks and 12 weeks,
and 12 weeks after termination of therapy. Similar to the results from Huber et al.’s
(1997) study, patients receiving Piracetam demonstrated significant improvement of
language functioning, but no improvement on the ADL or in perception measures.
Enderby et al. (1994) suggested that Piracetam is specifically improving language
functioning for individuals with aphasia. However, one might raise questions as to the
functional significance of these improvements if an index of daily living abilities does not
also improve.
In a large phase II study, De Deyn (1995) demonstrated benefit when Piracetam was
administered within 12 hours post-onset. However, in a later randomised placebocontrolled study, 927 patients were given intravenous Piracetam within 12 hours of stroke
onset. De Deyn et al. (1997) reported no difference in mortality or neurologic outcome at
12 weeks post-stroke. Post-hoc analysis revealed that individuals treated within 7 hours
of onset indeed showed a trend towards a better outcome (Hickenbottom & Grotta, 1998).
Taken overall, De Deyn and colleagues’ findings are consistent with the literature
regarding the limited time window in which neuroreplacement agents are effective in
treating stroke.
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
Despite a lack of comparability of the assessment measures in different studies, and the
small sample sizes used, a consensus emerges that both amphetamine and Piracetam are
promising neuroreplacement agents to study. In the past, these agents have always been
tested in combination with intensive language therapy. It should be noted that there is
every reason to believe that these drugs alone would be unlikely to be effective. Although
both amphetamine and Piracetam have been shown to improve learning in a variety of
populations, this learning occurs due to the pairing of therapy with pharmaceutics.
Presumably these drugs demonstrate efficacy in aphasics due to their ability to enhance
the relearning that is induced by the combination of speech-language therapy with drugs.
Further research of the pairing of therapy and neuroreplacement could expand to include
the investigation of the length of time benefits are available after termination of
combination therapy.
Neuroprotective agents have a complex method of action, typically directed at preventing
or salvaging the ischaemic penumbra after a stroke (Hickenbottom & Grotta, 1998).
While the previously mentioned studies in pharmacotherapy and neuroreplacement
focused on recovery of function, neuroprotective therapy involves protecting neurons and
minimising the extent of the lesion and the initial deficits. As noted earlier, researchers
have targeted the ischaemic penumbra, which contains potentially viable tissue in
patients with acute ischaemic stroke (Heiss & Graf, 1994). Protection of the penumbra
has been demonstrated in animal models of stroke using neuroprotective agents (Dorman
& Sandercock, 1996; Trembly, 1995). Human research with neuroprotective agents has
typically focused on reducing mortality and morbidity, and on broad measures of
outcome. As a result, discrete aspects of behaviour, such as language functioning, have
been left relatively unstudied. Due to the difference in outcome measurement, usefulness
of neuroprotection versus pharmacotherapy or neuroreplacement in aphasia should be
compared with caution. Although neuroprotection is not a direct ‘‘treatment’’ of aphasia,
the underlying principle is that by minimising destroyed tissue, deficits are reduced and
subsequent aphasia, and therefore the need for rehabilitation, is decreased. The theory
behind the following neuroprotective treatments has focused on three main areas:
prevention of glutamate-induced excitotoxicity, scavenging free radicals to mitigate their
cytotoxic effects, and repair of neuronal membranes. Each approach will be discussed in
Prevention of glutamate excitotoxicity
Researchers have hypothesised that interventions to reduce glutamate excitotoxicity
following an ischaemic event may minimise cell loss. Indeed, glutamate blockade may
explain one of the earliest successes in neuroprotection, when Wright and Ames (1964)
used sodium pentobarbital to reduce ischaemic brain damage in cats. The drug
intervention doubled the time frame in which global ischaemia could be reversibly
sustained in cats. Although unknown at that time, it has subsequently been shown that the
effects of this drug may have been due to blockade of glutamate receptors (Olney et al.,
1991). Since this original study, a number of pharmacologically distinct approaches have
been attempted to protect the brain from the glutamate-induced excitotoxicity following a
stroke. These approaches include drugs to prevent glutamate release (e.g., lubeluzole) and
drugs that block glutamate receptors such as N-methyl-D-aspartate (NMDA) antagonists
(e.g., Cerestat). It is also possible to prevent the subsequent effects of glutamate, for
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
example, with protein kinase inhibitors (e.g., GM-1) and calcium channel blockers (e.g.,
Prevention of excessive glutamate release. Lubeluzole is a compound that restricts
the release of glutamate, and might therefore be expected to prevent further damage in the
ischaemic penumbra (Heiss & Graf, 1994; Scheller et al., 1995). The use of lubeluzole
normalises neuronal excitability in the ischaemic penumbra (Buchkremer-Ratzmann &
Witte, 1995) and inhibits neurotoxicity induced by excessive glutamate activity (Lesage,
Peeters, & Leysen, 1994). For example, using a rat model, De Ryck et al. (1996), found
that lubeluzole administered 5 minutes after an ischaemic infarct was induced led to
reduced infarct volume 4 hours later.
Similar success has been found in a study investigating lubeluzole in acute ischaemic
stroke in humans (Diener et al., 1996). This study utilised double-blind, placebocontrolled procedures with stroke patients administered lubeluzole or a placebo control
within 6 hours of stroke onset, and again over a period of 5 days. Neurological function
was assessed on days 3, 5, 7, 14, and 28. The investigators found that lubeluzole
administration decreased mortality rate by 6% and led to a decreased number of patients
with severe disability (Diener et al., 1996). In addition, two combined trials on lubeluzole
for patients with mild to moderate strokes demonstrated a statistically significant
mortality reduction as well as increased patient outcome (Hantson & Wessel, 1998).
However, a phase III trial using lubeluzole between 0 and 8 hours post-onset had
reportedly negative results (Hickenbottom & Grotta, 1998). This suggests that findings
with lubeluzole may not be as clear as previously thought and further studies should be
Receptor antagonists of glutamate. Two glutamate antagonists, MK-801 and
GYKI52466 , have been studied in both rats and cats (Sutton, Hovda, & Feeney, 1989)
with little research completed in humans. Both agents were found to aid in neuronal
protection when administered up to 2 hours after the ischaemic event. In a number of
studies, these antagonists have also been shown to block the excitotoxic cascade of
ischaemia (Lyden & Lonzo, 1994). Furthermore, the authors found that combining MK801 and a GABA agonist (muscimol) was more effective in rats than either agent used
alone. Specifically, the use of these two agents protected visual-spatial learning as
measured by the Morris water maze, in rats with induced cerebral infarcts. Muscimol may
block the voltage-gated intracellular calcium inflow associated with glutamate, and in
combination with receptor antagonist for glutamate, appeared to provide the best
neuroprotection (Lyden & Lonzo, 1994; see Traystman, 1994 for a further explanation).
NMDA antagonists. N-methyl-d-aspartate (NMDA) is a widespread amino acid
neurotransmitter that may be involved in neuronal plasticity and learning (Cooper,
Bloom, & Roth, 1996). Glutamate acts on several different postsynaptic receptors, one of
which is the NMDA receptor. NMDA has been implicated in decreasing the likelihood of
widespread extent of damage in animal models of focal cerebral ischaemia because of
this interaction with glutamate (Lees, 1997). Evidence for contribution of the NMDA
receptor to ischaemic injury has been shown in recent research with animals (McCulloch,
1992). For example, NMDA antagonists have shown considerable promise in animal
models of stroke, particularly when administered prior to the onset of trauma (Bullock &
Fugisawa, 1992). For example, a non-competitive receptor antagonist of NMDA,
eliprodil, has been found to reduce the size of cortical infarction following middle
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
cerebral artery occlusion in mice and rats (Gotti, Benavides, MacKenzie, & Scatton,
1990). Similar results have been shown following traumatic brain damage in rats with the
volume of cortical damage decreased by 60% after 6 days of eliprodil administration
(Toulmond, Serrano, Benavides, & Scatton, 1993). Of most interest is the surprising
result that a similar sparing of cortical damage could be seen even when the first
administration of neuroprotectant was delayed until 12 hours post-trauma (Toulmond et
al., 1993). This suggests that neuroprotection by NMDA antagonists may have a longer
window of opportunity than other techniques.
Another neuroprotectant that has been studied in animal models is Cerestat. It has been
shown that Cerestat (a non-competitive NMDA antagonist) reduced cellular damage in
rats if the drug was given 15 minutes after occlusion of the middle cerebral artery
(Minematsu et al., 1993). In addition, Cerestat has been investigated in human trials with
equivocal results. Unfortunately, initial phase III human trials of Cerestat were
discontinued in December 1997 due to safety and efficacy concerns (Cambridge
Neuroscience Inc., 1997; Turrini, 1996). However, a recent human trial suggests that
Cerestat is ‘‘reasonably tolerated’’ (Dyker et al., p. 2041), although increases in blood
pressure and central nervous system effects were observed. Another NMDA antagonist
examined in human trials is Selfotel, which was evaluated in a randomised, double-blind,
placebo-controlled dose escalation phase IIa human study. In this study, Selfotel’s safety
and tolerability was demonstrated; however, adverse neuropsychiatric side-effects were
reported (Grotta et al., 1995; cf. Hickenbottom & Grotta, 1998). In addition, two phase III
trials with Selfotel administered at 1.5 mg/kg within 6 hours post-onset were terminated
early due to an increase in mortality rates in the Selfotel group versus the placebo group
(Davis et al., 1995).
Inhibition of protein kinase C. Many of the excitotoxic effects of glutamate are
thought to be mediated, in part, by the translocation of protein kinase C to the cell
membrane, where it becomes activated. Thus, inhibition of glutamate induced protein
kinase C would be expected to mitigate against excitotoxicity. The ganglioside class of
drugs, of which monosialogangliosida (GM-1) is a member, has been associated with
nerve growth and repair (Carolei, Fieschi, Bruno, & Toffano, 1991). The protective
effects of GM-1 are thought to be achieved by blocking the effects of glutamate on
protein kinase C (Vaccarino, Guidotti, & Costa, 1987). In a randomised, placebocontrolled, double-blind, multicentre study conducted by Lenzi et al., (1994), patients
that received GM-1 as compared to placebo, experienced an average of 10%
improvement in terms of clinical severity. Clinical severity was determined by level of
consciousness, orientation, speech, and motor deficit assessed using the Canadian
Neurological Scale (Cote et al., 1986). The authors also noted that the greatest
improvement was found if GM-1 was presented less than 4 hours after the initial onset of
stroke, similar to that found in studies using other drugs. Other studies with GM-1 have
not been as promising. In a phase III human trial with GM-1, the Syngen Acute Stroke
Study (SASS; Alter, 1994), investigated mortality rates. Their results indicated similar
mortality rates between groups receiving GM-1 and groups receiving placebo.
Nevertheless, future studies with GM-1 have not been planned (Hickenbottom & Grotta,
Calcium channel blockade. The sudden increase in intracellular calcium associated
with a stroke can lead to activation of autolytic enzymes that ultimately cause cell death.
Blockade of the calcium channels using a drug such as Nimodipine (Gotoh et al., 1986)
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
has been shown to protect neurons from an influx of calcium in the rat. However, findings
suggest that Nimodipine administered in humans may reduce infarct severity only if the
drug is administered within 18 hours of stroke onset (American Nimodipine Study Group,
1991). One example of the neuroprotective effects can be demonstrated in a study
conducted by Popovic, Danks, and Siu (1993). They assessed the efficacy of Nimodipine
in preventing delayed ischaemic deficits resulting from aneurysmal subarachnoid
haemorrhage (SAH). In this study, Nimodipine treatment began as soon as a diagnosis
had been reached and continued for 12 days. Popovic et al. (1993) found that treatment
with Nimodipine after aneurysmal SAH reduced mortality and neurological deficits, and
benefits remained at follow-up 12 months after treatment. Roine, Kaste, Kinnune, and
Nikki (1987) also found benefits from Nimodipine for patients with global ischaemia. In
this study, patients resuscitated after ventricular fibrillation were given Nimodipine or a
placebo control. For those with prolonged cerebral ischaemia (greater than 10 minutes),
Nimodipine was shown to markedly increase 1-year survival from 8% (2/26) to 47% (8/
17), suggesting that this drug had a neuroprotective function.
In contrast, Kaste et al. (1994) found no benefit on functional outcome following
treatment with Nimodipine, but this null finding could have been due to the amount of
time elapsed between the onset of stroke and the administration of the drug. In the Kaste
et al. (1994) study, only 19% of patients received Nimodipine within the first 6 hours, so
the vast majority probably received the drug well outside the window for effective
treatment. Indeed, most researchers agree that the maximum time window for
Nimodipine, and possibly other therapeutic drugs, is 3 hours after the initial onset of
stroke symptoms (Fisher & Bogousslavsky, 1993). Currently, this drug is being evaluated
further in the Very Early Nimodipine Use in Stroke (VENUS) study, where the time
window should not exceed 12 hours (de Keyser, 1997). However, this time window may
indeed prove to be too large as well, and without benefits from this study, the use of
Nimodipine may be discontinued (Hickenbottom & Grotta, 1998).
In summary, results from pharmaceutics that prevent glutamate excitation are equivocal
at best. While there appears to be some success in various areas of research within this
field, other research indicates that this success is limited. Difficulties include increased
side-effects and mortality rates in addition to time of administration restrictions. As
indicated in previous sections, further human research is necessary to determine the
potential of this class of neuroprotective agents.
Free radical scavenging
A second area of neuroprotective research deals with the scavenging of free radicals.
Although free radicals are formed in the brain under normal conditions, healthy cells are
able to neutralise them with free radical scavengers. However, free radicals are not
neutralised in ischaemic regions of the brain, and may increase during stroke and
intensify the severity of damage. Damage occurs as a reduction in the amount of available
oxygen decreases production of free radical scavengers. Xue, Slivka, and Buchan, (1992)
found that tirilazad, a free radical scavenger, reduced the amount of cerebral damage in
rats with induced cortical infarction. The Safety Study of Tirilazad Mesylate in patients
with Acute Ischaemic Stroke Investigators (STIPAS; 1994) examined 111 ischaemic
stroke patients and determined that patients given tirilazad within 12 hours of stroke were
able to tolerate this drug. It is unfortunate that no language or cognitive recovery data
were collected in this study, as the large sample sizes were such that even modest benefits
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
would have been detectable. The results of efficacy studies of tirilazad as an intervention
in adults suffering from stroke are less clear. On the one hand, tirilazad has been found to
reduce mortality in individuals with subarachnoid haemorrhage (Kassell et al., 1996) and
ischaemic stroke (STIPAS, 1994). However, other safety and efficacy studies have shown
no significant differences using tirilazad in patients with acute cerebral ischaemia (Peters
et al., 1996; RANTTAS investigators, 1996). Even more problematic, a European study
for severe head injury had to terminate a study of tirilazad prematurely due to excess
mortality in the experimental group (Marshall & Marshall, 1995). Thus, while its use as a
free radical scavenger in principle suggests value in neuroprotection, further studies are
needed to determine its safety and worth in stroke rehabilitation.
Membrane repair
Citicoline is an intermediate in the biosynthetic pathway of the structural phospholipids of
cell membranes (Secades & Frontera, 1995), and so may perform a neuroprotective
function by assisting in the repair of injured cell membranes. Following an ischaemic
event, citicoline may limit the number of cells that die and may aid the brain in repairing
damaged circuits or creating new ones (National Stroke Association, 1997). Initial research
in this area was conducted with animals. For example, Yamamoto, Shimizu, and Okamiya
(1990), administered citicoline to rats 20, 80, and 140 minutes post-ischaemia and anoxia
induced by treatment with nitrogen, and assessed the effects 48 hours after the anoxia. It
was found that citicoline led to a significant decrease in the incidence of neurological
deficits in rats, especially when administered at the shorter intervals (20 and 80 minutes)
post-anoxia (Yamamoto et al., 1990; cf. Kakihana, Fukuda, Suno, & Nagaoko, 1988). In
human studies, it was found that patients in the advanced clinical trials using citicoline
demonstrated 20–30% better scores on tests of cognition than those who did not receive the
drug (National Stroke Association, 1997). Further human research by Clark et al. (1999)
found conflicting results. Clark et al. (1999) reported that citicoline was safe but showed no
clear effectiveness when all patients were considered. However, post hoc analyses
suggested that those individuals with moderate to severe stroke, as opposed to mild, might
show improved outcome with citicoline (Clark et al., 1999). Therefore citicoline may be
beneficial only for individuals with moderate to severe stroke.
A newer neuroprotective agent called clomethiazole reached phase III trials in North
America in 1997 (Green, 1998). Clomethiazole has been reported to enhance GABA
receptor activity, which could help diminish glutamate release (Hales & Lambert, 1992).
A phase III study with 560 patients demonstrated benefits in patients with large cortical
infarcts (Wahlgren & the CLASS Group, 1997). Further studies by Wahlgren et al. (1999)
tested the efficacy and safety of clomethiazole in a double-blind placebo-controlled trial
in 1360 patients. They reported that clomethiazole is safe for patients; however, no longterm benefits for patients were observed (Wahlgren et al., 1999).
In summary, neuroprotective agents have demonstrated efficacy in salvaging tissues and
increasing recovery after an ischaemic stroke. Many drugs are quite promising, although
no single neuroprotective agent has been shown to prevent major functional loss after
stroke. Current directions in therapy include combining neuroprotective agents with
behavioural therapy and neuroreplacement approaches. One important limitation
associated with neuroprotection is the need to administer drugs very early post-stroke.
It is a clinical and experimental challenge to diagnose and treat the patient with
neuroprotective agents given the narrow time window of approximately 3 hours.
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
In ischaemic strokes due to embolism, attempts have been made to reduce the duration of
the ischaemic episode by using drugs to dissolve the embolus, and thus restore blood flow
to the affected brain region, thereby reducing subsequent deficits such as aphasia. This is
a separate approach to preventing damage in that it seeks to prevent or limit damage by
restoring blood flow. Thrombolytics are often termed ‘‘clot-busters’’, as their function is
to break down an embolus, and thus, unlike neuroprotective agents, they do not work at
the level of the neuron. This approach is clearly inapplicable in the case of haemorrhagic
strokes, where their administration can increase the degree of brain damage, even fatally.
Therefore it is crucial to determine whether a stroke is ischaemic or haemorrhagic prior to
the initiation of this treatment. The two main thrombolytic agents used are streptokinase
and tissue plasminogen activator (tPA), although other thrombolytic drugs have
occasionally been studied.
This facilitates the breakdown and dissolution of formed clots by converting inactive
plasminogen to its active form, plasmin (Sherry & Gustafson, 1985). In turn, plasmin has
been shown to break down fibrin clots, which then reopens the occluded blood vessels
found in ischaemic stroke (Ciccone, 1996). However, it has been found in some studies
that the use of streptokinase even for an embolic stroke can lead to intracranial
haemorrhage (O’Connor et al., 1990). For example, the Multicentre Acute Stroke Trial–
Italy (1995) conducted a study comparing and combining streptokinase and aspirin,
which has anticoagulant effects. Disturbingly, this study found that streptokinase
significantly increased the risk of early death in acute stroke patients if the drug was
given in combination with aspirin. It is important to note that in this study streptokinase
was administered up to 6 hours after the onset of symptoms. This means that some
proportion of the participants received treatment more than 3 hours after stroke onset, a
time limit that has been suggested by a number of studies (Fischer, 1997). Using
streptokinase later than the 3-hour time window may result in what has been termed an
ischaemic–haemorrhagic cycle. In this, the initial ischaemic event is followed by a later
haemorrhagic event that causes additional damage to the brain. Additional studies could
be done to test the validity of streptokinase if given within a more restricted time frame of
perhaps 3 hours. The importance of early administration is underscored by the Australian
Streptokinase (ASK) Trial Study Group (Donnan et al., 1996). The results of their study
showed that administration of streptokinase up to 4 hours post symptom onset led to an
increase in morbidity and mortality. In contrast, treatment with streptokinase within 3
hours was found to be safer, but did not show significant benefits over placebo (Donnan
et al., 1996).
Tissue plasminogen activator (tPA)
This acts on clots in a similar way to streptokinase, but is much more strongly activated in
the presence of fibrin, making it likely that tPA may be more efficacious in the
dissolution of clots (Loscalzo & Braunwald, 1988). Treatments involving tPA have been
generally positive, demonstrating increased percentages of stroke victims who walk away
with little or no disabilities (Barinaga, 1996). For example, Haley et al. (1993) found that
six patients treated with tPA within 90 minutes of stroke onset had significantly improved
scores on the Stroke Scale after 24 hours. A full-scale trial of tPA by the NINDS rt-PA
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
Study Group (1995) noted that 31% of patients treated within 3 hours of the initial onset
of stroke showed complete or nearly full recovery within the first 3 months after the
stroke, as compared to 20% of the untreated patients, a difference that was statistically
significant. Further analysis of the NINDS data revealed that there was a benefit for
patients in every category of severity of stroke (Lyden, 1999; NINDS TPA Stroke Study
Group, 1997). Similar findings were also reported by Hacke et al. (1995) after tPA was
administered to patients up to 6 hours post-onset.
Although many studies suggest that the use of tPA is promising, the drug is not
without risks. In a manner similar to streptokinase, tPA has been found to cause cerebral
haemorrhage in some stroke patients (Sloan & Gore, 1992). Further, Hacke et al. (1995)
found that tPA was effective only in a subgroup of stroke patients with moderate to
severe neurologic deficits and without extended infarct signs on an initial computerised
tomography (CT) scan. Findings with tPA consistently reveal significant side-effects if
treatment is begun later than 6 hours post-onset (The NINDS rt-PA Study Group, 1995).
For this reason, Fischer (1997), among others, argues that tPA should be used only in the
first 3 hours after stroke onset.
Thrombolytic drugs are useful in removing the clots that cause ischaemic damage, but the
risk of haemorrhage requires extreme caution in administration of the drug. Similar to
neuroprotective agents, thrombolytic drugs should be administered very early post-stroke.
Again, the clinical and experimental challenge is to diagnose and treat the patient with
such a narrow time window of 3 hours or less.
It is important to appreciate both the strengths and weaknesses of using animal models to
understand human rehabilitation. Although animal models obviously cannot directly
study aphasia, they may be very informative in constraining the necessary human trials
that could ultimately lead to improved recovery from aphasia. Amphetamine has been
studied with animals and subsequently led to clinical trials with humans (Clark &
Mankikar, 1979). Other drugs, such as tPA or Nimodipine have recently moved from
laboratory to clinical trials (American Nimodipine Study Group, 1992; Feeney, 1997;
Fischer, 1997). Animal studies have an important advantage over human studies in that
there is much greater ability to control the experimental conditions. Therefore, these
highly controlled situations are an excellent arena for screening possible pharmacological
agents that may aid in the recovery or protection of function following a stroke. If a drug
does not prove highly effective in such tightly controlled conditions, that drug will
probably not be of clinical use (Hachiniski, 1996). One specific form of control that has
proved very important is that of timing of administration. Using animal models has
allowed researchers to obtain a time course of the cascade that occurs during stroke, and
the time window that could be considered in drug therapy (Grotta, 1996). The time
window of 3 hours post-onset for reperfusion was initially suggested from animal models
(Yang & Betz, 1994).
Although animal studies can act as an important screen for a new drug or treatment
regimen, often the transfer to human trials has proved disappointing, with human studies
showing little or no benefit. The first and most obvious reason for this lack of transfer is
the fact that human trials have much less control over many experimental factors such as
lesion location and size. This may dramatically reduce the statistical power of the studies
with an increased variance in lesion localisation, size, and severity. Moreover, control
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
over experimental manipulations that are straightforward in animal studies may prove
challenging in human trials—the timing of drug administration is a perfect example.
Although it may be extremely easy to ensure that animals are treated within 30 or 60
minutes of injury, this would prove extremely difficult given the real-world situations in
which strokes occur (Grotta, 1995) and, of course, pre-treatment is not an option in
human studies.
Second, the experimental designs that are possible in animal studies may not be
feasible in human trials. For example, many animal studies do not compare the current
drug they are studying to other drugs or therapy. Instead they compare a new therapy to a
control condition in which no therapy is given. This strategy clearly increases the
statistical power of the experiment, and the likelihood of finding a significant effect.
However, in human studies it is simply not an option to withhold any treatment from one
group (Grotta, 1995). Moreover, human trials also differ in the types of outcome
measures that can be used. Thus, whereas animal models typically use outcome measures,
obtained within a few days of the ischaemic event, the appropriate measure for human
trials is functional outcome many months later (Grotta, 1996). As a result, drugs that lead
to a transient improvement may show promise in animal studies that is not seen in longerterm human studies.
A third and final source of differences may relate not to the actual results of
experiments, but to the dissemination of results by the process of publication. It has been
noted (e.g., Grotta, 1995) that negative results in animal studies are rarely published.
Despite the bias against publication of negative results, such results in human studies may
appear in the literature due to the valuable information they provide.
A challenge is to create a bridge between these highly controlled animal studies, and
the inevitable variability seen in human trials. Animal studies may determine which
factors need to be closely controlled for treatments to be effective. Human studies would
then emphasise tight experimental control over those factors shown to be predictive of
positive outcome in the animal studies. The use of carefully piloted human studies should
ensure correct dosage and determine side-effects and time window information (Grotta,
1996). There is a definite need for good clinical research to further investigate the area of
drug therapy of stroke and aphasia, particularly in conjunction with speech-language
therapy. Future studies should include blind or double-blind procedures where
appropriate, and always employ placebo control groups to partial out the effects of
recovery that are not due to the drug or procedure being studied.
One consensus emerging from research on therapy for aphasia is that neuroprotective
agents show promise, but they must be administered within a very short time window—
perhaps only 3 hours after stroke onset. The evidence found with amphetamine and
Piracetam strongly suggests that pairing intensive language therapy with pharmaceutics
could lead to much improvement in recovery from aphasia (Feeney et al., 1982; Poeck,
Huber, & Horlacher, 1993). Therefore, drug therapy will not replace traditional speech
and language therapy but can be used to augment its effectiveness. Another emerging
consensus in the literature is that there is great difficulty in treating or preventing aphasia
with a single drug. There are increased positive effects when a combination of drugs is
used (Aronowski , Strong, & Grotta, 1996b; Onal et al., 1997). Therefore research points
to a need for combination drug therapy in the protection and treatment of stroke and
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
Currently there are a number of studies examining combinations of drugs in treating
stroke during the acute stage to maximise neuroprotection by using complementary
approaches. It has been argued that such combinations might result in more complete
protection of the ischaemic area than would a single compound (Aronowski et al.,
1996b). One such combination treatment currently being studied in animals is tPA and
Citicoline (Andersen et al., 1999). This combination would be used to prevent
significant damage to the neurons after the onset of a stroke. TPA would be used to
dissolve the clot, restoring blood supply to the brain’s tissues, and Citicoline would
aid in brain cell repair. Another example of combination therapy involves a study
using Citicoline and MK-801 in rats conducted by Onal et al. (1997). Citicoline is
important in the generation of phospholipids (Aronowski , Strong, & Grotta, 1996a),
while MK-801 is a potent, noncompetitive NMDA receptor antagonist that blocks the
excitotoxic sequelae of ischaemia, reduces infarct size, and improves neurological
outcome (Minematsu & Fisher, 1993; Onal et al., 1997). The combination study (Onal
et al., 1997) demonstrated a reduced infarct volume in rats after experiencing a
temporary focal cerebral ischaemia. Onal et al. (1997) noted that neither drug was
effective when administered by itself. A third example of combination neuroprotective
therapy involved the use of lubeluzole and diaspirin cross-linked hemoglobin
(DCLHb), which is a ‘‘blood substitute’’ and not a drug (Aronowski et al., 1996b,
p.1571). DCLHb is believed to operate by increasing the ‘‘offloading’’ of oxygen to
tissues (Bowes, Burhop, & Zivin, 1994). As mentioned previously, lubeluzole prevents
the increase in extracellular glutamate concentrations after ischaemia (Scheller et al.,
1995), and DCLHb has been shown to ameliorate ischaemic damage in rat and rabbit
stroke models (Bowes et al., 1994; Cole et al., 1992; Cole et al., 1993). It was found
that the combination of the neuroprotectant and the blood substitute were complementary. Lubeluzole worked to reduce the size of the infarcted region while DCLHb
delayed the onset of ischaemic damage (Aronowski et al., 1996b). Finally, other
combination research was initiated regarding a combination of lubeluzole and tPA;
however, it was interrupted due to reported negative findings with a phase III study
using lubeluzole independently (Hickenbottom & Grotta, 1998).
The goal of the combined approaches under study thus far has been simply to
minimise the initial lesion by different neuroprotectant approaches. Another level of
combination in terms of therapy is to be expected as these approaches transfer to humans.
In most human cases, such strategies might lead to a reduced size of infarct and reduction
in deficits, but nonetheless it might be expected that some deficits would remain. Future
treatment regimens might include subsequent treatment with pharmaceutics such as
amphetamine or Piracetam in order to assist in the restoration of lost function during
intensive language therapy. Although such a multi-stage strategy would seem well
designed in principle, almost no clinical research has so far investigated the effects of
combining acute use of neuroprotective agents with the use of pharmacotherapy during
The pharmacology of reduction and treatment of aphasia following stroke has progressed
rapidly in recent years. An increasing number of drugs demonstrating clinical
significance have been approved and studied in clinical trials across the world. Research
in these areas of pharmacotherapy and neuroprotection presents realistic and exciting new
therapy trends in rehabilitation. Although single mechanisms rarely solve the complex
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
dysfunctions of the brain, combination therapy holds much promise for the future
treatment of stroke and aphasia. We might expect to see an initial acute management
regimen that employs a combination of neuroprotectant approaches with later
pharmacotherapy combined with intensive language therapy. This area of research is
extremely important in helping to increase the efficiency and possibly the efficacy of
treatment for stroke patients. It holds the hope of both an increase in the quality of
rehabilitation and recovery, and also a decrease in the resources used in rehabilitation.
Albert, M.L., Bachman, D.L., Morgan, A., & Helm-Estabrooks, N. (1988). Pharmacotherap y for aphasia.
Neurology, 38, 877–879.
Alter, M. (1994). Ganglioside GM1 in acute ischemic stroke. The SASS trial. Stroke, 25(6), 1141–1148.
American Nimodipine Study Group (1992). Clinical trial of Nimodipine in acute ischemic stroke. Stroke, 23(1),
Andersen, M., Overgaard, K., Meden, P., Boysen, G., & Choi, S.C. (1999). Effects of citicoline combined with
thrombolytic therapy in rate embolic stroke model. Stroke, 30(7), 1464–1471.
Aronowski, J., Strong, R., & Grotta, J.C. (1996a). Citicoline for treatment of experimental focal ischemia:
Histologic and behavioral outcome. Neurology Research, 6, 570–574.
Aronowski, J., Strong, R., & Grotta, J.C. (1996b). Combined neuroprotection and reperfusion therapy for stroke:
Effect of Lubeluzol e and diaspirin cross-linked hemoglobin in experimental focal ischemia. Stroke, 27,
Bachman, D.L., & Albert, M.L. (1990). The pharmacotherap y of aphasia: Historical perspective and directions
for future research. Aphasiology, 4(4), 407–413.
Barinaga, M. (1996). Finding new drugs to treat stroke. Science, 272, 1996.
Benson, D.F., & Ardila, A. (1996). Aphasia: A clinical perspective. New York: Oxford University Press.
Bergman, P.S., & Green, M. (1951). Aphasia: Effect of intravenous sodium amytal. Neurology, 1, 471–475.
Billow, B.W. (1949). Observation of the use of sodium amytal in the treatment of aphasia. Medical Record, 162,
Bowes, M.P., Burhop, K.E., & Zivin, J.A. (1994). Diaspirin cross-linked hemoglobin improves neurological
outcome following reversible by not irreversible CNS ischemia in rabbits. Stroke, 25, 2253–2257.
Brailowsky, S. (1988). Therapeutic approaches in subjects with brain lesions. In D.G. Stein, & B.A. Sabel
(Eds.), Pharmacological approache s to the treatment of brain and spinal cord injury. New York: Pellum
Buchkremer-Ratzmann , I., & Witte, O.W. (1995). Pharmacologica l reduction of electrophysiologica l diaschisis
after photothromboti c ischemia in rat neocortex. European Journal of Pharmacology, 320, 103–109.
Bullock, R., & Fugisawa, H. (1992). The role of glutamate antagonists for the treatment of CNS injury. Journal
of Neurotrauma, 9(2), S443–S462.
Cambridge Neuroscience Inc. (1997, December). Cambridge neuroscienc e will not restart accrual in stroke
trial. Available web page: /new/new.htm
Carolei, A., Fieschi, C., Bruno, R., & Toffano, G. (1991). Monosialogangliosid e GM1 in cerebral ischemia.
Cerebrovascula r Brain Metabolism Review, 3, 134–157.
Ciccone (1996). Pharmacology in rehabilitation. Philadelphia: F.A. Davis Company.
Clark, A.N.G., & Mankikar, G.D. (1979). d-Amphetamine in elderly patients refractory to rehabilitation
procedures. Journal of the American Geriatrics Society, 27(4), 174–177.
Clark, W.M., Williams, B.J., Selzer, K.A., Zweifler, R.M., Sabounjian, L.A., & Gammans, R.E. for the
Citicoline Stroke Study Group (1999). A randomized efficacy trial of citicoline in patients with acute
ischemic stroke. Stroke, 30, 2592–2597.
Cohen, S., & Muller, W. (1993). Effects of Piracetam on N-methyl-D-aspartat e receptor properties in the aged
mouse brain. Pharmacology, 47, 217–222.
Cole, D.J., Schell, R.M., Drummond, J.C., Przybelski, R.J., & Marcantonio, S. (1993). Focal cerebral ischemia
in rats: Effect of hemodilution with alpha-alpha cross-linked hemoglobin on brain injury and edema.
Canadian Journal of Neurological Science, 20, 30–36.
Cole, D.J., Schell, R.M., Przybelski, R.J., Drummond, J.C., & Bradley, K. (1992). Focal cerebral ischemia in
rats; effect of hemodilution with alpha-alpha cross-linked hemoglobin on CBF. Journal of Cerebral Blood
Flow Metabolism, 12, 971–976.
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
Cooper, J.R., Bloom, F.E., & Roth, R.H. (1996). The biochemical basis of neuropharmacolog y. New York:
Oxford University Press.
Cote, R., Hachinski, V.C., Shurwell, B.L., Norris, J.W., & Wolfson, C. (1986). The Canadian Neurological
Scale: A preliminary study in acute stroke. Stroke, 17(4), 731–734.
Crisostomo, E.A., Duncan, P.W., & Dawson, D.V. (1988). Evidence that amphetamine with physical therapy
promotes recovery of motor function in stroke patients. Annals of Neurology, 23(1), 94–97.
Darley, F.L. (1982). Aphasia. Philadelphia: W.B. Saunders.
Darley, F.L., Keith, R.L., & Sasanuma, S. (1977). The effect of alerting and tranquilizing drugs upon the
performance of aphasic patients. Clinical Aphasiology, 7, 91–96.
Davis S.M., Albers G.W., Diener H.C., Lees K.R., & Norris J. (1995). Termination of acute stroke studies
involving Selfotel treatment. ASSIST Steering Committee. Lancet, 349, (9044), 32.
De Deyn, P.P. (1995). Piracetam in Acute Stroke (PASS). European Journal of Neurology, 2, S2, 7.
De Deyn, P.P., Reuck, J.D., Debertdt, W., Vlietinck, R., & Orgogozo, J.M. (1997). Treatment of acute ischemic
stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke, 28(12),
de Keyser, J. (1997). Opportunities for neuroprotection . Acute Stroke Management, 2, 11–14.
De Renzi, E., & Vignolo, L.A. (1962). The Token Test: A sensitive test to detect receptive disturbances in
aphasics. Brain, 85, 665–678.
De Ryck, M., Keersmaekers, R., Duytschaever , H., Claes, C., Clincke, G., Janssen, M., & Van Reet, G. (1996).
Lubeluzole protects sensorimotor function and rescues infarct size in a photochemica l stroke model in rats.
The Journal of Pharmacolog y and Experimental Therapeutics, 279, 748–758.
Diener, H.C., Hacke, W., Hennerici, M., Radber, J., Hantson, L., & De Keyser, J., for the Lubeluzole
International Study Group (1996). Lubeluzole in acute ischemic stroke: A double-blind , placebo-controlle d
phase II trial. Stroke, 27, 76–81.
Donnan, G.A., Davis, S.M., Chambers, B.R., Gates, P.C., Hankey, G.J., McNeil, J.J., Rosen, D., Stewart-Wynne,
E.G., & Tuck, R.R., Streptokinase for acute ischeamic stroke with relationship to time of administration:
Australian Streptokinase (ASK) Trial study group (1996). Journal of the American Medical Association,
276, 961–966.
Dorman, P.J., & Sandercock, P.A.G. (1996). Considerations in the design of clinical trial of neuroprotective
therapy in acute stroke. Stroke, 27, 1507–1515.
Dyker, A.G., Edwards, K.R., Fayad, P.B., Hormes, J.T., & Lees, K.R. (1999). Safety and tolerability study of
aptiganel hydrochloride in patients with an acute ischemic stroke. Stroke, 30, 2038–2042.
Dyker, A.G., & Lees, K.R. (1998). Duration of neuroprotectiv e treatment for ischemic stroke. Stroke, 29,
Enderby, P., Broeckx, J., Hospers, W., Schildermans, F., & Deberdt, W. (1994). Effect of Piracetam on recovery
and rehabilitation after stroke: A double-blind , placebo-controlle d study. Clinical Neuropharmacolog y, 17,
Feeney, D.M. (1997). From laboratory to clinic: Noradrenergi c enhancemen t of physical therapy for stroke or
trauma patients. Advances in Neurology, 73, 383–394.
Feeney, D.M., Gonzalez, A., & Law, W.A. (1982). Amphetamine, haloperidol, and experience interact to affect
rate of recovery after motor cortex injury. Science, 217(27), 855–857.
Fischer, J. (1997). TPA for acute ischemic stroke. South Dakota, 13, 69–70.
Fisher, M., & Bogousslavsky , J. (1993). Evolving toward effective therapy for acute ischemic stroke. Journal of
the American Medical Association, 270(3), 360–364.
Fishman, R.A. (1986). Brain edema. In H.J.M. Barnett, J.P. Mohr, B.M. Stein, & F.M. Yatsu, (Eds.), Stroke, Vol
1 (pp. 119–126). New York: Churchill Livingstone.
Francis, A., & Pulsinelli, W. (1982). The response of GABAergic and cholinergi c neurons to transient cerebral
ischemia. Brain Research, 243, 271–278.
Freedman M., Alexander, M.P., & Naeser, M.A. (1984). Anatomic basis of transcortical motor aphasia.
Neurology, 34, 409–417.
Goodglass, H., & Kaplan, E. (1983). Boston Diagnostic Aphasia Examination. Philadelphia: Lea & Febiger.
[Distributed by Psychological Assessment Resources, Odessa, FL.]
Goldstein, K., & Scheerer, M. (1945). The Goldstein-Scheere r tests of abstract and concrete thinking. New
York: Psychological Corporation.
Gotoh, O., Mohamed, A., McCulloch, J., Graham, D., Harper, A., & Teasdale, G. (1986). Nimodipine and the
haemodynami c and histophatologi c consequence s of middle cerebral artery occlusion in the rat. Journal of
Cerebral Blood Flow and Metabolism, 6, 321–331.
Gotti, B., Benavides, J., MacKenzie, E.T., & Scatton, B. (1990). The pharmacotherap y of focal cortical ischemia
in the mouse. Brain Research, 522, 290–307.
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
Green, A.R. (1998). Clomethiazole (Zendra) in acute ischemic stroke: Basic pharmacology and biochemistry
and clinical efficacy. Pharmacology Therapy, 80(2), 123–147.
Grotta, J. (1995). Why do all drugs work in animals but none in stroke patients? Neuroprotectiv e therapy.
Journal of Internal Medicine, 237, 89–94.
Grotta, J. (1996). Rodent models of stroke limitations: What can we learn from recent clinical trials of
thrombolysis? Archives of Neurology, 53, 1067–1070.
Grotta, J., Clark, W., Coull, B., Pettigrew, L.C., Mackay, B., Goldstein, L.B., Meissner, I., Murphy, D., &
LaRue, L. (1995). Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with
acute ischemic stroke. Results of a phase IIa randomized trial. Stroke, 26(4), 602–605.
Gupta, S.R., & Mlcoch, A.G. (1992). Bromocriptine treatment of nonfluent aphasia. Archives of Physical and
Medical Rehabilitation, 73, 373–376.
Hachiniski, V. (1996). Relevance of rodent models of stroke. Archives of Neurology, 53, 1070.
Hacke, W., Kaste, M., Fieschi, C., Toni, D., Lesaffre, E., von Kummer, R., Boysen, G., Bluhmki, E., Hoxter, G.,
Mahagne, M., & Hennerici, M. for the ECASS Study Group (1995). Intravenous thrombolysis with
recombinan t Tissue Plasminogen Activator for acute hemispheri c stroke: The European Cooperative Acute
Stroke Study (ECASS). Journal of the American Medical Association, 2274, 1017–1025.
Hales, T.G., & Lambert, J.J. (1992). Modulation of GABAA and glycine receptors by chlormethiazole .
European Journal of Pharmacology, 21, 239–246.
Haley, E.C., Brott, T.G., Sheppard, G.L., Barson, W., Broderick, J., Marler, J.R., Kongable, G.L., Spilker, J.,
Massey, S., Hansen, C.A., & Torner, J.C., for the TPA Bridging Study Group (1993). Pilot randomized trial
of Tissue Plasminogen Activator in acute ischemic stroke. Stroke, 24, 1000–1004.
Hantson, L., & Wessel, T. (1998). Therapeutic benefits of lubeluzole in ischemic stroke. Stroke, 29, 287.
Hassid, E.I. (1995). Neuropharmacologica l therapy and motor recovery after stroke. Military Medicine, 160(5),
Hegde, M.N. (1994). A courseboo k on aphasia and other neurogeni c language disorders. San Diego, California:
Singular Publishing Group, Inc.
Heiss, W.D., & Graf, R. (1994). The ischemic penumbra. Current Opinions in Neurology, 7, 11–19.
Hemphill, D.E. (1951). Restoration of speech in severe aphasia by intravenous and oral Priscol. British Medical
Journal, 2, 891–892.
Hickenbottom , S.L., & Grotta, J. (1998). Neuroprotectiv e therapy. Seminars in Neurology, 18(4), 485–492.
Huber, W., Wilmes, K., Poeck, K., Van Vleymaen, B., & Deberdt, W. (1997). Piracetam as an adjunct to
language therapy for aphasia; a randomized double-blind placebo-controlle d pilot study. Archives of
Physical Medicine and Rehabilitation, 78, 245–250.
Kakihana, M., Fukuda, N., Suno, M., & Nagaoko, A. (1988). Effects of CDP-choline on neurogeni c deficits and
cerebral glucose metabolism in a rat model of cerebral ischemia. Stroke, 19, 217–222.
Kaplan, E.F., Goodglass, H., & Weintraub, S. (1993). The Boston Naming Test. Philadelphia: Lea & Febiger.
Kassell, N.F., Haley, E.C., Apperson-Hausen , C., & Alves, W.M. (1996). Randomized , double-blind, vehiclecontrolled trial of tirilazad mesylate in patients with anaurysmal hemorrhage —a cooperative study in Europe
and Australia. Journal of Neurosurger y, 84, 221–228.
Kaste, M., Fogelholm, R., Erila, T., Palomaki, H., Murros, K., Rissanen, A., & Sarna, S. (1994). A randomized,
double-blind , placebo-controlle d trial of Nimodipine in acute ischemic hemispheric stroke. Stroke, 25, 1348–
Kertesz, A. (1979). Aphasia and associated disorders. New York: Grune & Stratton.
Kertesz, A. (1982). Western Aphasia Battery. San Antonio, TX: The Psychological Corporation.
Kuriansky, J., & Gurland, B. (1976). The performance test of activities of daily living. International Journal of
Aging and Human Development, 7, 343–352.
Last, J.M. (1995). A dictionary of epidemiology (3rd Edn.). New York: Oxford University Press.
Lenzi, G.L., Grigoletto, F., Gent, M., Roberts, R.S., Walker, M.D., Easton, J.D., Carolei, A., Dorsey, F.C.,
Rocca, W.A., Bruno, R. (1994). Early treatment of stroke with monosialogangliosid e GM-1. Efficacy and
safety results of the Early Stroke Trial. Stroke, 25, 1552–1558.
Lesage, A.S., Peeters, L., & Leysen, J.E. (1994). Lubeluzole, a novel long-term neuroprotectant , inhibits the
glutamate-activate d nitric oxide synthase pathway. The Journal of Pharmacology and Experimental
Therapeutics, 279, 759–766.
Lees, K.R. (1997). Cerestat and other NMDA antagonist s in ischemic stroke. Neurology, 49(Supp 4), S66–S69.
Linn, L. (1947). Sodium amytal in treatment of aphasia. Archives of Neurology and Psychiatry, 58, 357–358.
Loscalzo, J., & Braunwald, E. (1988). Tissue Plasminogen Activator. The New England Journal of Medicine,
319, 925–931.
Lyden, P.D. (1999). Thrombolysis for acute stroke. Progress in Cardiovascular Disease, 42(3), 175–183.
Lyden, P.D., & Lonzo, L. (1994). Combination therapy protects ischemic brain in rats. Stroke, 25(1), 189–196.
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
MacLellan, E.L., Nicholas, L.E., Morley, G.K., & Brookshire, R.H. (1991). The effects of bromocriptine of
speech and language function in a man with transcortical motor aphasia. Clinical Aphasiology, 20, 145–156.
Mahoney, F.I., & Barthel, D.W. (1965). Functional evaluation: The Barthel Index. Maryland State Medical
Journal, 14, 61–65.
Marshall, L., & Marshall, S. (1995). Pitfalls and advances from the international tirilazad trial in moderate and
severe head injury. Journal of Neurosurger y, 12, 929–932.
Matsuo, Y., Yamasaki, Y., & Kogure, K. (1996). Inflammatory reaction after brain damage and prospective
therapy against damage impending cerebral infarction. Keio Journal of Medicine, 45, 270–274.
McCulloch, J. (1992). Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain
damage in man. British Journal of Clinical Pharmacology, 34, 106–114.
McIntosh, T.K. (1994). Neurochemica l sequelae of traumatic brain injury: Therapeutic implications.
Cerebrovascula r Brain Metabolism Review, 6, 109–162.
Mettler, C.C. (1947). History of medicine. Philadelphia: Blackstone.
Metz, B. (1971). Acetylcholine and experimental brain injury. Journal of Neurosurger y, 35, 523–528.
Minematsu, K., & Fisher, M. (1993). MK-801 reduces extensive infarction after suture middle cerebral artery
occlusion in rats. Cerebrovascula r Disease, 3, 99–104.
Minematsu, K., Fisher, M., Li, L., Davis, M.A., Knapp, A.G., Cotter, R.E., McBurney, R.N., & Sotok, C.H.
(1993). Effects of a novel NMDA agonist on experimental stroke rapidly and quantitatively assessed by
diffusion-weighte d MRI. Neurology, 43, 26–31.
Mlcoch, A.G., & Gupta, S.R. (1995). Pharmacologica l approache s to the treatment of aphasia. Topics in Stroke
Rehabilitation, 2(1), 40–48.
Multicentre Acute Stroke Trial–Italy (MAST-I) Group (1995). Randomised controlled trial of streptokinase,
aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet, 356, 8989, 1509–14.
National Stroke Association (1997). FDA approval may be next for Citicoline. Be Stroke Smart, 14(9), 2.
NINDS rt-PA Stroke Study Group (1995). Tissue Plasminogen Activator for acute ischemic stroke. The New
England Journal of Medicine, 333, 1581–1587.
NINDS TPA Stroke Study Group (1997). Generalized efficacy of rt-PA for acute stroke. Stroke, 28, 2119–2125.
O’Connor, C.M., Califf, R.M., Massey, E.W., Mark, D.B., Candela, R.J., Abbotsmith, C., George, B., Stack,
R.S., & Aronson, L. (1990). Stroke and acute myocardial infarction in the thrombolytic era: Clinical
correlates and long term prognosis. Journal of the American College of Cardiology, 16, 533–540.
Olney, J.W., Labruyere, J., Wang, G., Wozniak, D.F., Price, M.T., & Sesma, M.A. (1991). NMDA antagonist
neurotoxicity: Mechanism and prevention. Science, 254, 1515–1518.
Onal, M.Z., Fuhai, L., Tatlisumak, T., Locke, K., Sandage, B.W., & Fisher, M. (1997). Synergistic effects of
Citicoline and MK-801 in temporary experimental focal ischemia in rats. Stroke, 28, 1060–1065.
Peters, G.R., Hwang, L.-J., Musch, B., Brosse, D.M., & Orgogozo, J.M. (1996). Safety and efficacy of 6 mg/kg/
day tirilazad mesylate in patients with acute ischemic stroke (TESS study). Stroke, 27, 195.
Poeck, K., Huber, W., & Horlacher, R. (1993). Piracetam as an add-on treatment to intensive speech therapy for
aphasia. Presented at ‘‘Recent advances in the treatment of neurodegenerativ e disorders and cognitive
dysfunction’’, Collegium Internationale Neuro-Psychopharmacologicum , Capri, Italy, May 1–3.
Popovic, E.A., Danks, R.A., & Siu, K.H. (1993). Experience with Nimodipine in aneurysmal subarachnoi d
haemorrhage. The Medical Journal of Australia, 158, 91–94.
Porch, B.E. (1981). The Porch Index of Communicative Ability. Palo Alto, CA: Consulting Psychologists
Porch, B.E. (1983). Porch Index of Communicative Ability (manual). Palo Alto, CA: Consulting Psychologists
RANTTAS Investigators (1996). Randomized trial of tirilazad mesylate in patients with acute stroke. Stroke,
27(9), 1453–1458.
Reilly, P.M., & Bulkley, G.B. (1990). Tissue injury by free radicals and other toxic oxygen metabolites. British
Journal of Surgery, 77, 1323–1324.
Roine, R.O., Kaste, M., Kinnune, A., & Nikki, P. (1987). Safety and efficacy of Nimodipine in resuscitation of
patients outside hospital. British Medical Journal, 294, 20–22.
Rothman, S.M. (1983). Synaptic activity mediates death of hypoxi c neurons. Science, 220, 536–537.
Sabe, L., Leiguarda, R., & Starkstein, S.E. (1992). An open-label trial of bromocriptine in nonfluent aphasia.
Neurology, 42, 1637–1638.
Sabe, L., Salvarezza, G., Cuerva, A.G., Leiguarda, R., & Starkstein, S. (1995). A randomized, double-blind ,
placebo-controlled study of bromocriptine in nonfluent aphasia. Neurology, 45, 2272–2274.
Sarno, J.E., Rusk, H.A., Diller, L., & Sarno, M.T. (1972a). The effect of hyperbaric oxygen on the mental and
verbal ability of stroke patients. Stroke, 3, 10–15.
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
Sarno, M.T. (1969). The Functional Communication Profile: Manual of directions. New York: Institute of
Rehabilitation Medicine, New York University Medical Center.
Sarno, M.T., Sarno, J.E., & Diller, L. (1972b). The effect of hyperbari c oxygen on communication function in
adults with aphasia secondary to stroke. Journal of Speech and Hearing Research, 15, 42–48.
Schallert, T., & Hernandez, T.D. (1998). GABAergic drugs and neuroplasticit y after brain injury: Impact on
functional recovery. In L.B. Goldstein (Ed.), Restorative neurology : Advances in pharmacotherap y for
recovery after stroke (pp. 91–120). New York: Futura Publishing Company, Inc.
Scheinberg, P. (1991). The biologic basis for the treatment of acute stroke. Neurology, 41, 1867–1873.
Scheller, D., Kolb, J., Szathmary, S., Zacharias, E., De Ryck, M., Van Reempts, J., Clincke, G., & Tegtmeier, F.
(1995). Extracellular changes of glutamate in the peri-infarct zone: Effect of Lubeluzole. Journal of
Cerebral Blood Flow Metabolism, 15, S379.
Secades, J.J., & Frontera, G. (1995). CDP-choline: Pharmacologica l and clinical review. Methods and Findings
in Experimental and Clinical Pharmacolog y, 17, Suppl 13, 2–54.
Sherry, S., & Gustafson, E. (1985). The current and future use of thrombolytic therapy. Annual Review of
Pharmacological Toxicology, 25, 413.
Siesjo, B.K. (1992). Pathophysiolog y and treatment of focal cerebral ischemia. Part I: Pathophysiology . Journal
of Neurosurger y, 77, 169–184.
Sloan, M.A., & Gore, J.M. (1992). Ischemic stroke and intracranial hemorrhage following thrombolytic therapy
for acute myocardial infarction: A risk–benefit analysis. American Journal of Cardiology, 69, 21A–38A.
Small, S.L. (1994). Pharmacotherap y of aphasia: A critical review. Stroke, 25, 1282–1289.
Smith, S., & Turton, E.C. (1951). Restoration of speech in severe aphasia by intravenous and oral Priscol. British
Medical Journal, 891–892.
STIPAS investigators (1994). Safety study of tirilazad mesylate in patients with acute stroke. Stroke, 25, 418–
Stoll, L., Schubert, T., & Muller, W.E. (1991). Age-related deficits of central muscarinic cholinergi c receptor
function in the mouse: Partial restoration by chronic Piracetam treatment. Neurobiology of Aging, 13, 39–44.
Stolyarova, L., Kadykov, A., Kistenev, B., Varakin, Y., Yurchenko , A., Davydov, V., & Volkov, V. (1978). The
role of Piracetam in complex rehabilitation therapy of patients with residual manifestations of a cerebral
stroke. In E.A. Babayan, N.V. Lebedeva, G.M. Rudenko, & N.K. Shagako (Eds.), Nootropil in neurologica l
and psychiatric practice: Materials of a symposium. Moscow, 26 May.
Sutton, R.L., Hovda, D.A., & Feeney, D.M. (1989). Amphetamine accelerates recovery of locomotor function
following bilateral frontal cortex ablation in cats. Behavioral Neuroscience, 103(4), 837–841.
Taylor, M.L. (1965). A measuremen t of functional communication in aphasia. Archives of Physical Medicine
and Rehabilitation, 46, 101–107.
Toulmond, S., Serrano, A., Benavides, J., & Scatton, B., (1993). Prevention by Eliprodil (SL 82.0715) of
traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window. Brain Research, 620(1),
Traystman, R.J. (1994). Editorial comment. Stroke, 25, 196.
Trembly, B. (1995). Clinical potential for the use of neuroprotective agents: A brief overview. Annals of the New
York Academy of Sciences, 765, 1–20.
Turkstra, L. (1997). Neuroprotection following stroke and head injury. Neurophysiolog y and Neurogenic Speech
and Language Disorders, 7(3), 3–7.
Turrini, R. (1996). A pivotal safety and efficacy trial of Cerestat (Apitaganel HCl/CNS) in acute ischemic stroke
patients: Dose-escalating safety study. Stroke, 27, 173.
Vaccarino, F., Guidotti, A., & Costa, E. (1987). Ganglioside inhibition of glutamate-mediated protein kinase C
translocation in primary cultures of cerebellar neurons. Neurobiology, 84, 8707–8711.
von Herrschaft, H. (1987). Konnen Hirnleistungsstorunge n Medikamentos verbessert werden? Fortshritte der
Medizin, 105, 637–640. [Not able to obtain this article, therefore the information is presented as described in
Bachman & Albert, 1990.]
Wahlgren, N.G., & the Clomethiazole Acute Stroke Study Collaborative Group (1997). The Clomethiazole
Acute Stroke Study (CLASS). Cerebrovascula r Disease, 7, 19.
Wahlgren, N.G., Ranasinha, K.W., Rosolacci, T., Franke, C.L., van Erven, P.M.M., Ashwood, T., & Claesson,
L. for the CLASS Study Group (1999). Clomethiazole Acute Stroke Study (CLASS) results of a randomized,
controlled trial of clomethiazol e versus placebo in 1360 acute stroke patients. Stroke, 30, 21–28.
Walker-Batson, D., Devous, M.D., Curtis, S., Unwin, H., & Greenlee, P. (1990). Response to amphetamine to
facilitate recovery from aphasia subsequen t to stroke. Clinical Aphasiology, 20, 137–144.
Walker-Batson, D., Smith, P., Curtis, S., Unwin, H., & Greenlee, R. (1995). Amphetamine paired with physical
therapy accelerates motor recovery after stroke: Further evidence. Stroke, 26(12), 2254–2259.
Downloaded By: [EBSCOHost EJS Content Distribution] At: 13:00 18 February 2008
Walker-Batson, D., Unwin, H., Curtis, S., Allen, E., Wood, M., Smith, P., Devous, M.D., Reynolds, S., &
Greenlee, R.G. (1992). Use of amphetamine in the treatment of aphasia. Restorative Neurology and
Neuroscience, 4, 47–50.
West, R., & Stockel, S. (1965). The effect of meprobamat e on recovery from aphasia. Journal of Speech and
Hearing Research, 8, 57–62.
Whiting, S.E., Lincoln, N.B., Bhavani, G., & Cockburn, J. (1985). The Rivermead Perceptual Assessment
Battery. Windsor, UK: NFER Nelson.
Willmes, K., Huber, W., Poeck, K., & Poersch, M. (1988). Die Wirkung von Piracetam bei der logopaÈ dischen
Intensivtherapie von chronisch aphasischen Patienten. In H. Helmchen (Ed.), Wirkungen und Wirksamkeit
von Nootropika. Berlin: Springer-Verlag. [Not able to obtain this article, therefore the information is
presented as described in Bachman & Albert, 1990.]
Willmes, K., Poeck, K., Weniger, D., & Huber, W. (1980). Der Aachener Aphasie Test. Differentielle ValiditaÈ t.
Nervenarzt, 51, 553–560.
Wright, R.H., & Ames, A. III. (1964). Measurement of maximal permissible cerebral ischemia and a study of its
pharmacologica l prolongation. Journal of Neurosurger y, 7, 567–574.
Xue D., Slivka A., & Buchan A.M. (1992). Tirilazad reduces cortical infarction after transient by not permanent
focal cerebral ischemia in rats. Stroke, 23, 894–899.
Yamamoto, M., Shimizu, M., & Okamiya, H. (1990). Pharmacological actions of a new TRH analogue, YM14673, in rats subjected to cerebral ischemia and anoxia. European Journal of Pharmacolog y, 181, 207–214.
Yang, G.-Y., & Betz, A.L. (1994). Reperfusion-induce d injury to the blood–braine barrier after middle cerebral
artery occlusion in rats. Stroke, 25, 1658–1665.